Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meropenem: a new carbapenem antimicrobial

R D Pryka1, G M Haig

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Toledo, OH 43606.

The Annals of Pharmacotherapy
|September 1, 1994
PubMed
Summary

Meropenem, a new carbapenem antibiotic, shows comparable in vitro activity and pharmacokinetics to imipenem/cilastatin. This investigational drug demonstrates promise as a second-generation carbapenem, though further clinical data are needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-dose gabapentin pharmacokinetics and safety in healthy infants and children.

Journal of clinical pharmacology·2001
Same author

Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement.

The Journal of bone and joint surgery. American volume·2000
Same author

Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Clinical pharmacokinetics·1997
Same author

Vancomycin serum concentration monitoring: a continued debate.

The Annals of pharmacotherapy·1994
Same author

Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition.

Antimicrobial agents and chemotherapy·1993
Same author

Increase in serum digoxin concentrations after indomethacin therapy in a full-term neonate.

Pharmacotherapy·1992

Area of Science:

  • Microbiology and Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Carbapenem antibiotics represent a critical class of broad-spectrum antibacterial agents.
  • Imipenem/cilastatin is the sole carbapenem currently available for clinical use.
  • Meropenem is an investigational carbapenem antibiotic developed to potentially expand therapeutic options.

Purpose of the Study:

  • To describe the characteristics of meropenem.
  • To compare meropenem with imipenem/cilastatin regarding antimicrobial activity and pharmacokinetic properties.
  • To evaluate the preliminary clinical efficacy and safety of meropenem.

Main Methods:

  • Literature review of English language publications from MEDLINE and conference abstracts (1988-1992).
  • Assessment of study design and quality, focusing on in vitro susceptibility and pharmacokinetic analyses.
  • Inclusion of preliminary Phase 3 clinical trial data, primarily available in abstract form.

Main Results:

  • Meropenem exhibits broad-spectrum activity against Gram-positive and Gram-negative pathogens, including beta-lactamase producers.
  • Compared to imipenem, meropenem shows lower activity against Gram-positive organisms but enhanced activity against Enterobacteriaceae; activity against Pseudomonas aeruginosa is similar.
  • Pharmacokinetic profiles are comparable, with potential for greater tissue penetration; meropenem does not require cilastatin for administration.
  • Preliminary clinical trials suggest meropenem is as safe and effective as imipenem/cilastatin or ceftazidime for various infections.

Conclusions:

  • Meropenem demonstrates in vitro susceptibility patterns and pharmacokinetic disposition comparable to imipenem.
  • Meropenem shows potential as a significant advancement in the carbapenem class of antibiotics.
  • Further clinical data are necessary to fully establish the efficacy and safety of meropenem.

Related Experiment Videos